Determining venous thromboembolism risk in patients with adult-type diffuse glioma

2.

Marras

LC

,

Geerts

WH

,

Perry

JR

.

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

.

Cancer

.

2000

;

89

(

3

):

640

-

646

.

3.

Perry

JR

.

Thromboembolic disease in patients with high-grade glioma

.

Neuro Oncol

.

2012

;

14

(

suppl 4

):

iv73

-

iv80

.

4.

Jenkins

EO

,

Schiff

D

,

Mackman

N

,

Key

NS

.

Venous thromboembolism in malignant gliomas

.

J Thromb Haemost

.

2010

;

8

(

2

):

221

-

227

.

5.

Lee

AY

,

Levine

MN

.

Venous thromboembolism and cancer: risks and outcomes

.

Circulation

.

2003

;

107

(

23 suppl 1

):

I17

-

I21

.

6.

Semrad

TJ

,

O'Donnell

R

,

Wun

T

, et al.

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma

.

J Neurosurg

.

2007

;

106

(

4

):

601

-

608

.

7.

Timp

JF

,

Braekkan

SK

,

Versteeg

HH

,

Cannegieter

SC

.

Epidemiology of cancer-associated venous thrombosis

.

Blood

.

2013

;

122

(

10

):

1712

-

1723

.

8.

Smith

TR

,

Lall

RR

,

Graham

RB

, et al.

Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period

.

J Neurooncol

.

2014

;

120

(

2

):

347

-

352

.

9.

Briggs

RG

,

Lin

YH

,

Dadario

NB

, et al.

Optimal timing of post-operative enoxaparin after neurosurgery: a single institution experience

.

Clin Neurol Neurosurg

.

2021

;

207

:

106792

.

10.

Jo

JT

,

Schiff

D

,

Perry

JR

.

Thrombosis in brain tumors

.

Semin Thromb Hemost

.

2014

;

40

(

3

):

325

-

331

.

11.

Zwicker

JI

,

Karp Leaf

R

,

Carrier

M

.

A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation

.

J Thromb Haemost

.

2016

;

14

(

9

):

1736

-

1740

.

12.

Khoury

MN

,

Missios

S

,

Edwin

N

, et al.

Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism

.

Neurooncol Pract

.

2016

;

3

(

2

):

87

-

96

.

13.

Al Megren

M

,

De Wit

C

,

Al Qahtani

M

,

Le Gal

G

,

Carrier

M

.

Management of venous thromboembolism in patients with glioma

.

Thromb Res

.

2017

;

156

:

105

-

108

.

14.

Mantia

C

,

Uhlmann

EJ

,

Puligandla

M

,

Weber

GM

,

Neuberg

D

,

Zwicker

JI

.

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin

.

Blood

.

2017

;

129

(

25

):

3379

-

3385

.

15.

Jo

J

,

Donahue

J

,

Sarai

G

,

Petroni

G

,

Schiff

D

.

Management of venous thromboembolism in high-grade glioma: does low molecular weight heparin increase intracranial bleeding risk?

.

Neuro Oncol

.

2022

;

24

(

3

):

455

-

464

.

16.

Wong

JM

,

Panchmatia

JR

,

Ziewacz

JE

, et al.

Patterns in neurosurgical adverse events: intracranial neoplasm surgery

.

Neurosurg Focus

.

2012

;

33

(

5

):

E16

.

17.

Yust-Katz

S

,

Mandel

JJ

,

Wu

J

, et al.

Venous thromboembolism (VTE) and glioblastoma

.

J Neurooncol

.

2015

;

124

(

1

):

87

-

94

.

18.

Wang

TF

,

Wong

CA

,

Milligan

PE

,

Thoelke

MS

,

Woeltje

KF

,

Gage

BF

.

Risk factors for inpatient venous thromboembolism despite thromboprophylaxis

.

Thromb Res

.

2014

;

133

(

1

):

25

-

29

.

19.

Brandes

AA

,

Scelzi

E

,

Salmistraro

G

, et al.

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study

.

Eur J Cancer

.

1997

;

33

(

10

):

1592

-

1596

.

20.

Thaler

J

,

Ay

C

,

Kaider

A

, et al.

Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas

.

Neuro Oncol

.

2014

;

16

(

12

):

1645

-

1651

.

21.

Khorana

AA

,

Kuderer

NM

,

Culakova

E

,

Lyman

GH

,

Francis

CW

.

Development and validation of a predictive model for chemotherapy-associated thrombosis

.

Blood

.

2008

;

111

(

10

):

4902

-

4907

.

22.

Louis

DN

,

Perry

A

,

Wesseling

P

, et al.

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

.

Neuro Oncol

.

2021

;

23

(

8

):

1231

-

1251

.

23.

Horbinski

C

.

What do we know about IDH1/2 mutations so far, and how do we use it?

.

Acta Neuropathol

.

2013

;

125

(

5

):

621

-

636

.

24.

Unruh

D

,

Schwarze

SR

,

Khoury

L

, et al.

Mutant IDH1 and thrombosis in gliomas

.

Acta Neuropathol

.

2016

;

132

(

6

):

917

-

930

.

25.

Unruh

D

,

Mirkov

S

,

Wray

B

, et al.

Methylation-dependent tissue factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas

.

Clin Cancer Res

.

2019

;

25

(

2

):

747

-

759

.

26.

Unruh

D

,

Schwarze

SR

,

Khoury

L

, et al.

Mutant IDH1 and thrombosis in gliomas

.

Acta Neuropathol

.

2016

;

132

(

6

):

917

-

930

.

27.

Unruh

D

,

Zewde

M

,

Buss

A

, et al.

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers

.

Sci Rep

.

2019

;

9

(

1

):

8946

.

28.

Riedl

J

,

Preusser

M

,

Nazari

PM

, et al.

Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

.

Blood

.

2017

;

129

(

13

):

1831

-

1839

.

29.

Mir Seyed Nazari

P

,

Riedl

J

,

Preusser

M

, et al.

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism

.

J Thromb Haemost

.

2018

;

16

(

6

):

1121

-

1127

.

30.

Suzuki-Inoue

K

.

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

.

Blood

.

2019

;

134

(

22

):

1912

-

1918

.

31.

Tawil

N

,

Bassawon

R

,

Meehan

B

, et al.

Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles

.

Blood Adv

.

2021

;

5

(

6

):

1682

-

1694

.

32.

Watanabe

J

,

Natsumeda

M

,

Okada

M

, et al.

Podoplanin expression and IDH-wildtype status predict venous thromboembolism in patients with high-grade gliomas in the early postoperative period

.

World Neurosurg

.

2019

;

128

:

e982

-

e988

.

33.

Anand

M

,

Brat

DJ

.

Oncogenic regulation of tissue factor and thrombosis in cancer

.

Thromb Res

.

2012

;

129

(

suppl 1

):

S46

-

S49

.

34.

Bastida

E

,

Ordinas

A

,

Escolar

G

,

Jamieson

GA

.

Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis

.

Blood

.

1984

;

64

(

1

):

177

-

184

.

35.

Khorana

AA

,

Ahrendt

SA

,

Ryan

CK

, et al.

Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer

.

Clin Cancer Res

.

2007

;

13

(

10

):

2870

-

2875

.

36.

Manly

DA

,

Wang

J

,

Glover

SL

, et al.

Increased microparticle tissue factor activity in cancer patients with venous thromboembolism

.

Thromb Res

.

2010

;

125

(

6

):

511

-

512

.

37.

Rondon

AMR

,

Kroone

C

,

Kapteijn

MY

,

Versteeg

HH

,

Buijs

JT

.

Role of tissue factor in tumor progression and cancer-associated thrombosis

.

Semin Thromb Hemost

.

2019

;

45

(

4

):

396

-

412

.

38.

Thaler

J

,

Ay

C

,

Mackman

N

, et al.

Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients

.

J Thromb Haemost

.

2012

;

10

(

7

):

1363

-

1370

.

39.

Zwicker

JI

,

Liebman

HA

,

Neuberg

D

, et al.

Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy

.

Clin Cancer Res

.

2009

;

15

(

22

):

6830

-

6840

.

40.

Nikiforova

MN

,

Wald

AI

,

Melan

MA

, et al.

Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors

.

Neuro Oncol

.

2016

;

18

(

3

):

379

-

387

.

41.

Tritschler

T

,

Kraaijpoel

N

,

Le Gal

G

,

Wells

PS

.

Venous thromboembolism: advances in diagnosis and treatment

.

JAMA

.

2018

;

320

(

15

):

1583

-

1594

.

42.

Heagerty

PJ

,

Zheng

Y

.

Survival model predictive accuracy and ROC curves

.

Biometrics

.

2005

;

61

(

1

):

92

-

105

.

43.

R Development Core Team

. R: A language and environment for statistical computing.

R Foundation for Statistical Computing

;

2018

.

44.

Geddings

J

,

Aleman

MM

,

Wolberg

A

,

von Bruhl

ML

,

Massberg

S

,

Mackman

N

.

Strengths and weaknesses of a new mouse model of thrombosis induced by inferior vena cava stenosis: communication from the SSC of the ISTH

.

J Thromb Haemost

.

2014

;

12

(

4

):

571

-

573

.

45.

Khorana

AA

,

Connolly

GC

.

Assessing risk of venous thromboembolism in the patient with cancer

.

J Clin Oncol

.

2009

;

27

(

29

):

4839

-

4847

.

46.

Mandel

JJ

,

Youssef

M

,

Yust-Katz

S

, et al.

IDH mutation status and the development of venous thromboembolism in astrocytoma patients

.

J Neurol Sci

.

2021

;

427

:

117538

.

47.

Osada

Y

,

Saito

R

,

Miyata

S

, et al.

Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma

.

Brain Tumor Pathol

.

2021

;

38

(

3

):

218

-

227

.

48.

Dunbar

A

,

Bolton

KL

,

Devlin

SM

, et al.

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

.

Blood

.

2021

;

137

(

15

):

2103

-

2113

.

49.

Kaptein

FHJ

,

Stals

MAM

,

Kapteijn

MY

, et al.

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma

.

J Thromb Haemost

.

2022

;

20

(

7

):

1665

-

1673

.

50.

Diaz

M

,

Jo

J

,

Smolkin

M

,

Ratcliffe

SJ

,

Schiff

D

.

Risk of venous thromboembolism in grade II-IV gliomas as a function of molecular subtype

.

Neurology

.

2021

;

96

(

7

):

e1063

-

e1069

.

51.

Low

SK

,

Anjum

Z

,

Mahmoud

A

,

Joshi

U

,

Kouides

P

.

Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: a systematic review and meta-analysis

.

Thromb Res

.

2022

;

219

:

14

-

21

.

52.

Geddings

JE

,

Mackman

N

.

Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients

.

Blood

.

2013

;

122

(

11

):

1873

-

1880

.

53.

Sartori

MT

,

Della Puppa

A

,

Ballin

A

, et al.

Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role

.

Thromb Haemost

.

2013

;

110

(

2

):

378

-

385

.

54.

Sartori

MT

,

Della Puppa

A

,

Ballin

A

, et al.

Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles

.

J Neurooncol

.

2011

;

104

(

1

):

225

-

231

.

55.

Hisada

Y

,

Alexander

W

,

Kasthuri

R

, et al.

Measurement of microparticle tissue factor activity in clinical samples: a summary of two tissue factor-dependent FXa generation assays

.

Thromb Res

.

2016

;

139

:

90

-

97

.

56.

Taillibert

S

,

Taillandier

L

,

Le Rhun

E

.

Venous thrombosis in patients with high-grade glioma

.

Curr Opin Oncol

.

2015

;

27

(

6

):

516

-

521

.

57.

Sasaki

M

,

Knobbe

CB

,

Itsumi

M

, et al.

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

.

Genes Dev

.

2012

;

26

(

18

):

2038

-

2049

.

58.

Huang

Y

,

Ding

H

,

Luo

M

, et al.

Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma

.

Support Care Cancer

.

2022

;

30

(

7

):

6063

-

6069

.

59.

Hegi

ME

,

Diserens

AC

,

Gorlia

T

, et al.

MGMT gene silencing and benefit from temozolomide in glioblastoma

.

N Engl J Med

.

2005

;

352

(

10

):

997

-

1003

.